The impact of Perioperative Dexmedetomidine usage in prevention of Acute Kidney Injury in patients undergoing Whipple operations
Phase 4
Recruiting
- Conditions
- Anaesthesia
- Registration Number
- PACTR202408886014501
- Lead Sponsor
- national liver institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Adult patients (18 years or older) undergoing Whipple surgery.
Exclusion Criteria
Patients with pre-existing renal dysfunction (eGFR <60 mL/min/1.73 m2)
Major intraoperative events (e.g. severe hemodynamic instability, massive blood loss, massive blood products transfusion).
Allergy to Dexmedetomidine, unwilling to participate in the study will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method renal function tests urea and creatinine
- Secondary Outcome Measures
Name Time Method rine output in the first 24 hours postoperatively.<br>Incidence of delirium, hypotension, bradycardia, and prolonged mechanical ventilation within 48 hours postoperatively<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Dexmedetomidine target to prevent Acute Kidney Injury in Whipple operations?
How does Dexmedetomidine compare to standard-of-care anesthetics in preventing postoperative AKI in pancreatic surgery?
Which biomarkers are associated with response to Dexmedetomidine in high-risk AKI patients undergoing pancreatic resection?
What are the potential adverse events of perioperative Dexmedetomidine use in Whipple procedures and how are they managed?
Are there combination therapies involving Dexmedetomidine and nephroprotective agents for preventing AKI in complex abdominal surgeries?